Maze Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 141

Employees

  • Stock Symbol
  • MAZE

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $33.90
  • (As of Monday Closing)

Maze Therapeutics General Information

Description

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Contact Information

Website
www.mazetx.com
Formerly Known As
Genetic Modifiers NewCo
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 171 Oyster Point Boulevard
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 171 Oyster Point Boulevard
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (650)

Maze Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Maze Therapeutics Stock Performance

As of 16-Nov-2026, Maze Therapeutics’s stock price is $33.90. Its current market cap is $1.85B with 54.7M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$33.90 $34.34 $21.95 - $53.65 $1.85B 54.7M 712K -$2.67

Maze Therapeutics Financials Summary

As of 30-Sep-2026, Maze Therapeutics has a trailing 12-month revenue of $20M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,159,162 1,633,837
Revenue 20,000 0 167,500 0
EBITDA (162,445) (140,496) 52,049 (98,281)
Net Income (151,472) (131,120) 52,231 (100,415)
Total Assets 511,557 397,127 240,542 71,504
Total Debt 59,643 23,306 26,628 49,623
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Maze Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Maze Therapeutics‘s full profile, request access.

Request a free trial

Maze Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Maze Therapeutics‘s full profile, request access.

Request a free trial

Maze Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop no
Drug Discovery
South San Francisco, CA
141 As of 2025

Madison, WI
 

Philadelphia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Maze Therapeutics Competitors (45)

One of Maze Therapeutics’s 45 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Madison, WI
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
Xenetic Biosciences Corporation Framingham, MA
Inhibrx Formerly VC-backed La Jolla, CA
Cantex Pharmaceuticals Formerly VC-backed Weston, FL
You’re viewing 5 of 45 competitors. Get the full list »

Maze Therapeutics Patents

Maze Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026193408-A2 Apol1 inhibitors and methods of use thereof Pending 14-Mar-2025
WO-2026183125-A1 Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof Pending 25-Feb-2025
WO-2026183127-A1 Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof Pending 25-Feb-2025
WO-2026183128-A1 Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof Pending 25-Feb-2025
WO-2026183129-A1 Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof Pending 25-Feb-2025 C07D471/04
To view Maze Therapeutics’s complete patent history, request access »

Maze Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Maze Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Maze Therapeutics‘s full profile, request access.

Request a free trial

Maze Therapeutics Investments (2)

Maze Therapeutics’s most recent deal was a Joint Venture with Broadwing Bio. The deal was made on 07-Dec-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Broadwing Bio 07-Dec-2020 Joint Venture Biotechnology
Contour Therapeutics 07-Dec-2020 Joint Venture Drug Discovery
To view Maze Therapeutics’s complete investments history, request access »

Maze Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Maze Therapeutics’s complete esg history, request access »

Maze Therapeutics FAQs

  • When was Maze Therapeutics founded?

    Maze Therapeutics was founded in 2018.

  • Where is Maze Therapeutics headquartered?

    Maze Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of Maze Therapeutics?

    Maze Therapeutics has 141 total employees.

  • What industry is Maze Therapeutics in?

    Maze Therapeutics’s primary industry is Drug Discovery.

  • Is Maze Therapeutics a private or public company?

    Maze Therapeutics is a Public company.

  • What is Maze Therapeutics’s stock symbol?

    The ticker symbol for Maze Therapeutics is MAZE.

  • What is the current stock price of Maze Therapeutics?

    As of 16-Nov-2026 the stock price of Maze Therapeutics is $33.90.

  • What is the current market cap of Maze Therapeutics?

    The current market capitalization of Maze Therapeutics is $1.85B.

  • What is Maze Therapeutics’s current revenue?

    The trailing twelve month revenue for Maze Therapeutics is $20M.

  • Who are Maze Therapeutics’s competitors?

    Centrose, Aro Biotherapeutics, Xenetic Biosciences, Inhibrx, and Cantex Pharmaceuticals are some of the 45 competitors of Maze Therapeutics.

  • What is Maze Therapeutics’s annual earnings per share (EPS)?

    Maze Therapeutics’s EPS for 12 months was -$2.67.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process